Seatbelts in CAR therapy: How Safe Are CARS?

Pharmaceuticals

Kentaro Minagawa¹  Xiaoou Zhou²  Shin Mineishi¹  Antonio Di Stasi¹ 

[1] Bone Marrow Transplantation and Cellular Therapy, University of Alabama at Birmingham, Birmingham, AL 35294-3300, USA; E-Mails:;Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030-2399, USA; E-Mail:

关键词: chimeric antigen receptor;    suicide gene;    safety switch;    adoptive immunotherapy;    cell therapy;   

DOI  :  10.3390/ph8020230

来源: mdpi

【 摘 要 】

T-cells genetically redirected with a chimeric antigen receptor (CAR) to recognize tumor antigens and kill tumor cells have been infused in several phase 1 clinical trials with success. Due to safety concerns related to on-target/off-tumor effects or cytokine release syndrome, however, strategies to prevent or abate serious adverse events are required. Pharmacologic therapies; suicide genes; or novel strategies to limit the cytotoxic effect only to malignant cells are under active investigations. In this review, we summarize results and toxicities of investigations employing CAR redirected T-cells, with a focus on published strategies to grant safety of this promising cellular application.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.